SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SELLERS ROBERT W.A.

(Last)

(First)

(Middle)

ONE EDWARDS WAY

(Street)

IRVINE

92614

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/20/2014

3. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	VP, Corporate Controller

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	20,570⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Acquire)	05/10/2008⁽²⁾	05/09/2014	Common Stock	3,300	$24.42	D
Employee Stock Option (Right to Acquire)	05/08/2009⁽³⁾	05/07/2015	Common Stock	3,400	$27.77	D
Employee Stock Option (Right to Acquire)	05/07/2010⁽⁴⁾	05/06/2016	Common Stock	4,800	$31.47	D
Employee Stock Option (Right to Acquire)	05/13/2011⁽⁵⁾	05/12/2017	Common Stock	6,480	$50.96	D
Employee Stock Option (Right to Acquire)	05/14/2014⁽⁶⁾	05/13/2020	Common Stock	5,210	$71.57	D
Employee Stock Option (Right to Acquire)	05/09/2013⁽⁷⁾	05/08/2019	Common Stock	4,340	$85.45	D
Employee Stock Option (Right to Acquire)	05/12/2012⁽⁸⁾	05/11/2018	Common Stock	4,060	$89.23	D

Explanation of Responses:

1. This amount includes 1,620 shares purchased under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.

2. This option was granted on May 10, 2007 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program. It became exercisable commencing one year after the grant date in four equal annual installments.

3. This option was granted on May 8, 2008 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program. It became exercisable commencing one year after the grant date in four equal annual installments.

4. This option was granted on May 7, 2009 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program. It became exercisable commencing one year after the grant date in four equal annual installments.

5. This option was granted on May 13, 2010 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program. The first three installments became exercisable on May 13, 2011, May 13, 2012 and May 13, 2013 respectively, and the final installment becomes exercisable on May 13, 2014.

6. This option was granted on May 14, 2013 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program. It becomes exercisable in four equal annual installments beginning May 14, 2014.

7. This option was granted on May 9, 2012 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program. The first installment became exercisable on May 9, 2013, and the next three installments become exercisable on May 9, 2014, May 9, 2015 and May 9, 2016.

8. This option was granted on May 12, 2011 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program. The first two installments became exercisable on May 12, 2012 and May 12, 2013, respectively, and the remaining two installments become exercisable on May 12, 2014 and May 12, 2015.

Remarks:

Exhibit List: Exhibt 24 - Power of Attorney

	Ifigenia Protopappas, Attorney-in-fact	03/03/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.